The effects of levetiracetam and a new 4-phenylpyrrolidone derivative GIZh-290 in a closed cross-maze in BALB/c and C57BL / 6 mice

The study was aimed to compare the psychopharmacological effects of 2 anticonvulsant drugs levetiracetam ((S)-2-(2-oxopyrrolidin-1-yl) butanamide) and the new compound, GIZh-290 (2-oxo-4-phenylpyrrolidine-1-yl) acetic acid) on behavioral spectra of inbred mice BALB/c and C57BL/6 under conditions of "closed cross-maze" test. It was found that after 5-fold i.p. injections levetiracetam (600 mg/kg/day) reduced the cognitive and motor ability of C57BL/6 mice, while in BALB/c mice the drug increased anxiety and diminished motor activity. In contrast, the substance GIZh-290 (5 mg/kg/day, i.p.) had no effect in C57BL/6. Compound GIZh-290 (5 mg/kg/day, 5 days, ip) does not affect the behavior of C57BL/6 mice, but depressed the motor activity in BALB/c mice.

противоэпилептический препарат, леветирацетам, соединение ГИЖ-290, мыши BALB/c и C57BL/6, ноотропное действие, тревожность, двигательная активность, закрытый крестообразный лабиринт, anticonvulsant, levetiracetam, 4-phenylpyrrolidone derivative, mice, BALB/c, C57BL/6, nootropic action, anxiety, motor activity, closed cross-maze test

1. Ковалёв И.Г., Воронина Т.А., Литвинова С.А., Жмуренко Л.А., Мокрое Г.В. Сравнение противосудорожных и мнемотропных свойств новых производных 4-фенилпирролидона, леветирацетама и пираце-тама. Эксперим. и клин. Фармакол. 2017; (в печати).

2. Jones J.E. Treating anxiety disorders in children and adolescents with epilepsy: What do we know? Epilepsy & Behavior. 2014; 39: 137-142.

3. Brand Ch., Mula M. Anxiety disorders in people with epilepsy. Epilepsy & Behavior. 2016; 59: 87-91.

4. Васильева Е.В., Салимов Р.М., Ковалёв Г.И. Влияние интраназального и внутрибрюшинного введений пептидов семакса и ноопепта на поведенческие характеристики мышей BALB/c. Фармакокинетика и фармакодинамика. 2016; 2: 31-36.

5. Salimov R.M. Behavioral patterns related to alcohol use in rodents: a factor analysis. Alcohol. 1999; 17: 157-162.

6. Kanner A.M., Hesdorffer D.C. Neuropsychiatric complications of epilepsy. In: H.Stefan and W.H. Theodore, editors. Handbook of Clinical Neurology, Vol.107 (3rd series) Epilepsy, Part I. Elsevier B.V.; 2012; 461-482.

7. Ortinski P., Meador K.J. Cognitive side effects of antiepileptic drugs. Epilepsy & Behavior. 2004; 5: S60-S65.

8. Mukhin K.Y., Pylaeva O.A. Efficacy and Tolerability of Levetiracetam (Keppra®) in the Treatment of Epilepsy: Review of Literature. Russian Journal of Child Neurology. 2015; 2 (10): 38.

9. Cramer J.A., De Rue K., Devinsky O. et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4 (2): 124-32.

10. Mula M., Sander J.W. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety. 2007; 30(7): 555-67.